ApoC-III gene polymorphisms and risk of coronary artery disease

Oliviero Olivieri; Chiara Stranieri; Antonella Bassi; Barbara Zaia; Domenico Girelli; Francesca Pizzolo; Elisabetta Trabetti; Suzanne Cheng; Michael A. Grow; Pier Franco Pignatti; Roberto Corrocher

Journal of Lipid Research (Sep 2002)

ApoC-III gene polymorphisms and risk of coronary artery disease

Oliviero Olivieri,
Chiara Stranieri,
Antonella Bassi,
Barbara Zaia,
Domenico Girelli,
Francesca Pizzolo,
Elisabetta Trabetti,
Suzanne Cheng,
Michael A. Grow,
Pier Franco Pignatti,
Roberto Corrocher

Affiliations

Oliviero Olivieri: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Chiara Stranieri: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Antonella Bassi: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Barbara Zaia: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Domenico Girelli: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Francesca Pizzolo: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Elisabetta Trabetti: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Suzanne Cheng: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Michael A. Grow: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Pier Franco Pignatti: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
Roberto Corrocher: Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy; Department of Human Genetics, Roche Molecular System, Alameda, CA, USA

Journal volume & issue: Vol. 43, no. 9
pp. 1450 – 1457

Abstract

Read online

Several polymorphisms in the apolipoprotein C-III (apoC-III) gene have been associated with hypertriglyceridemia, but the link with coronary artery disease risk is still controversial. In particular, apoC-III promoter sequence variants in the insulin responsive element (IRE), constitutively resistant to downregulation by insulin, have never been investigated in this connection. We studied a total of 800 patients, 549 of whom had angiographically documented coronary atherosclerosis, whereas 251 had normal coronary arteriograms. We measured plasma lipids, insulin, apoA-I, apoB, and apoC-III and assessed three polymorphisms in the apoC-III gene, namely, T-455C in the IRE promoter region, C1100T in exon 3, and Sst1 polymorphic site (S1/S2) in the 3′ untranslated region. Each variant influenced triglyceride levels, but only the T-455C (in homozygosity) and S2 alleles influenced apoC-III levels. In coronary artery disease (CAD) patients, 18.6% were homozygous for the −455C variant compared with only 9.2% in CAD-free group (P < 0.001).In logistic regression models, homozygosity for −455C variant was associated with a significantly increased risk of CAD (OR = 2.5 and 2.18 for unadjusted and adjusted models, respectively) suggesting that it represents an independent genetic susceptibility factor for CAD.

Published in Journal of Lipid Research

ISSN: 0022-2275 (Print); 1539-7262 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry
Website: https://www.journals.elsevier.com/journal-of-lipid-research

About the journal

Abstract

Keywords